Dogwood to Participate in the 2026 Maxim Growth SummitGlobeNewsWire · Oct 6, 2026
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialGlobeNewsWire · Sep 14, 2026
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain TranscriptSeeking Alpha · Sep 2, 2026
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain TreatmentMarketBeat · Sep 1, 2026
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026GlobeNewsWire · Aug 17, 2026
Dogwood Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 13, 2026Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.14 | -$0.34 | Miss |
| May 14, 2026 | -$0.22 | -$0.15 | Beat |
| Mar 18, 2026 | -$0.86 | -$0.26 | Beat |
| Nov 6, 2025 | -$1.23 | -$8.20 | Miss |
| Aug 13, 2025 | -$1.26 | -$1.99 | Miss |
| May 8, 2025 | -$0.77 | -$8.45 | Miss |